These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Abiraterone acetate and prednisolone for metastatic castration-resistant prostate cancer failing androgen deprivation and docetaxel-based chemotherapy: a phase II bridging study in Korean and Taiwanese patients. Kwak C; Wu TT; Lee HM; Wu HC; Hong SJ; Ou YC; Byun SS; Rhim HY; Kheoh T; Wan Y; Yeh H; Yu MK; Kim CS Int J Urol; 2014 Dec; 21(12):1239-44. PubMed ID: 25099185 [TBL] [Abstract][Full Text] [Related]
24. Androgen deprivation therapy in castrate-resistant prostate cancer: how important is GnRH agonist backbone therapy? Merseburger AS; Hammerer P; Rozet F; Roumeguère T; Caffo O; da Silva FC; Alcaraz A World J Urol; 2015 Aug; 33(8):1079-85. PubMed ID: 25261259 [TBL] [Abstract][Full Text] [Related]
25. Efficacy of docetaxel in castration-resistant prostate cancer patients with intraductal carcinoma of the prostate. Yamamoto A; Kato M; Matsui H; Ishida R; Kimura T; Funahashi Y; Sassa N; Matsukawa Y; Kamihira O; Hattori R; Gotoh M; Tsuzuki T Int J Clin Oncol; 2018 Jun; 23(3):584-590. PubMed ID: 29397469 [TBL] [Abstract][Full Text] [Related]
26. Management of metastatic castration-resistant prostate cancer: A focus on radium-223: Opinions and suggestions from an expert multidisciplinary panel. Baldari S; Boni G; Bortolus R; Caffo O; Conti G; De Vincentis G; Monari F; Procopio G; Santini D; Seregni E; Valdagni R Crit Rev Oncol Hematol; 2017 May; 113():43-51. PubMed ID: 28427521 [TBL] [Abstract][Full Text] [Related]
27. Chemotherapy following radium-223 dichloride treatment in ALSYMPCA. Sartor O; Hoskin P; Coleman RE; Nilsson S; Vogelzang NJ; Petrenciuc O; Staudacher K; Thuresson M; Parker C Prostate; 2016 Jul; 76(10):905-16. PubMed ID: 27004570 [TBL] [Abstract][Full Text] [Related]
31. Radium-223 dichloride: a new paradigm in the treatment of prostate cancer. Anido Herranz U; Fernández Calvo O; Afonso Afonso FJ; Rodríguez Martínez de Llano S; Lázaro Quintela M; León Mateos L; Vázquez Estévez S; Antón Aparicio LM Expert Rev Anticancer Ther; 2015 Mar; 15(3):339-48. PubMed ID: 25555355 [TBL] [Abstract][Full Text] [Related]
32. The Role of PCA 3 as a Prognostic Factor in Patients with Castration-resistant Prostate Cancer (CRPC) Treated with Docetaxel. Bourdoumis A; Chrisofos M; Stasinou T; Christopoulos P; Mourmouris P; Kostakopoulos A; Deliveliotis C Anticancer Res; 2015 May; 35(5):3075-9. PubMed ID: 25964598 [TBL] [Abstract][Full Text] [Related]
38. Co-introduction of a steroid with docetaxel chemotherapy for metastatic castration-resistant prostate cancer affects PSA flare. Shiota M; Yokomizo A; Takeuchi A; Kiyoshima K; Inokuchi J; Tatsugami K; Shiga KI; Koga H; Yamaguchi A; Naito S; Eto M BJU Int; 2016 Dec; 118(6):880-884. PubMed ID: 26991851 [TBL] [Abstract][Full Text] [Related]
39. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer]. Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258 [TBL] [Abstract][Full Text] [Related]
40. Practical guide to the use of radium 223 dichloride. Den RB; Doyle LA; Knudsen KE Can J Urol; 2014 Apr; 21(2 Supp 1):70-6. PubMed ID: 24775727 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]